A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 985-994

  Garcia Manero, Guillermo ^a   Khoury, Hanna J ^b   Jabbour, Elias ^a   Lancet, Jeffrey ^c   Winski, Shannon L ^d   Cable, LouAnn ^d   Rush, Selena ^d   Maloney, Lara ^d   Hogeland, Grant ^d   Ptaszynski, Mieke ^d   Calvo, Monica Cabrero ^a   Bohannan, Zach ^a   List, Alan ^c   Kantarjian, Hagop ^a   Komrokji, Rami ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ARRY 614; AZACITIDINE; CORTICOSTEROID; DECITABINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGFILGRASTIM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEXMETINIB; PROTEIN KINASE INHIBITOR; UREA;

ACNE; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATAXIA; ATRIAL FIBRILLATION; BONE MARROW; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; HUMAN; HYPERURICEMIA; HYPOKALEMIA; INTESTINE PERFORATION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; QT PROLONGATION; RASH; SCORING SYSTEM; TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; FEMALE; HUMANS; INDAZOLES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RECEPTOR, TIE-2; TREATMENT OUTCOME; UREA;

EID: 84929466299     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1765     Document Type: Article

References (36)

1. Nimer SD Myelodysplastic syndromes. Blood 2011; 111: 4841-51.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
3. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-65.
4. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-51.
5. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, DelCanizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-64.
6. Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep 2011; 6: 145-53.
7. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 692-701.
8. Ades L, Itzykson R, Fenaux P. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. Semin Hematol 2012; 49: 323-29.
9. Joeckel TE, Lubbert M. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Semin Hematol 2012; 49: 330-41.
10. Giagounidis AA Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes. Semin Hematol 2012; 49: 312-22.
11. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322-7.
12. Prebet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica 2013; 98:e18-9.
13. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009; 33: 1594-8.
14. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010; 116: 2174-9.
15. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109: 1705-14.
16. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-85.
17. Cowan KJ, Storey KB. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol 2003; 206: 1107-15.
18. Parcharidou A, Raza A, Economopoulos T, Papageorgiou E, Anagnostou D, Papadaki T, et al. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1999; 62: 19-26.
19. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-54.
20. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002; 75: 289-97.
21. Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res 2009; 33: 340-3.
22. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 2013; 27: 2177-86.
23. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, et al. Tolllike receptor alterations in myelodysplastic syndrome. Leukemia 2013; 27: 1832-40.
24. Zhou L, Opalinska J, Verma A. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell Cycle 2007; 6: 534-7.
25. Keith T, Araki Y, Ohyagi M, Hasegawa M, Yamamoto K, Kurata M, et al. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 2007; 137: 206-15.
26. Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, et al. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer 2011; 105: 975-82.
27. Koch K. The design and early development of the p38/Tie2 inhibitor, ARRY-614, in hematologic cancers [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr ED37.
28. Winski SL, Freeman BB, Remmers AE, Carter LL, Wright AD, Munson MC, et al. ARRY-614, an inhibitor of p38 MAP kinase and angiogenic targets, is active in preclinical models of hematological malignancies and significantly reduces ex-vivo cytokine production in normal human subjects. In 7th International Symposium on Targeted Anti-Cancer Therapeutics. Amsterdam, The Netherlands. 2009. p. 23-25.
29. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
30. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-25.
31. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006; 108: 4170-7.
32. Shahjahan M, Dunphy CH, Ewton A, Zu Y, Monzon FA, Rice L, et al. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Am J Clin Pathol 2008; 130: 635-41.
33. Peng H, Wen J, Zhang L, Li H, Chang CC, Zu Y, et al. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes. Mol Biosyst 2012; 8: 1366-74.
34. Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, et al. Role of the p38 mitogen-activated protein kinase pathway incytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005; 65: 9029-37.
35. Lebedeva S, Jens M, Theil K, Schwanhausser B, Selbach M, Landthaler M, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell 2011; 43: 340-52.
36. Mufson R, Gesner TB. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 1987; 69: 1485-90.